Advantages and Disadvantages of ARV Components
Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 AU Comment: Doravirine The non-nucleoside reverse transcriptase inhibitor doravirine (DOR), was approved by the TGA in 2020 as a single drug or as a fixed dose combination with TDF and lamivudine (3TC). DOR/TDF/3TC […]
ARV Components or Regimens Not Recommended as Initial Therapy
DHHS Last Updated: September 2022 RV Components or Regimens Reasons for Not Recommending as Initial Therapy Combination INSTI + NNRTI CAB plus RPV (PO or IM) This regimen only is approved for people who have achieved viral suppression on another ARV regimen. It has not been studied as initial ARV regimen. DTG plus RPV This regimen only […]
What to Start
This section has information on What to Start. Please click on the below links or follow the table of contents to access the information you are looking for. Initial Combination ARV Regimens for People with HIV Selecting an ART regimen Nucleoside Reverse Transcriptase Inhibitor Integrase Strand Transfer Inhibitor–Based Regimens Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens Protease […]
Virologic Failure
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: Australian Special Access Scheme for ARV treatments In heavily treatment-experienced patients, where treatment options are limited by drug resistance, toxicities or other issues, enrolment in a clinical trial of a new antiretroviral agent (if available), or use of an agent not yet TGA-approved […]
Poor CD4 Cell Recovery
Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression DHHS Last Updated: June 2021Australian Commentary Last Updated: July 2023 AU Comment: Poor CD4 cell recovery and persistent inflammation despite viral suppression Current DHHS recommendations are suitable for implementation in Australia, including the following points: In individuals with viral suppression, adding ARV drugs or switching […]
Optimising ART in the Setting of Virologic Suppression
Optimizing Antiretroviral Therapy in the Setting of Viral Suppression DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 Panel’s Recommendations for Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression Key Considerations and Panel’s Recommendations Advances in antiretroviral (ARV) treatment and a better understanding of HIV drug resistance have made it possible to consider […]
Discontinuation or Interruption of ARV
Discontinuation or Interruption of Antiretroviral Therapy DHHS Last Updated: January 2022Australian Commentary Last Updated: July 2023 AU Comment: Ibalizumab (IBA) Ibalizumab (IBA) a monoclonal antibody that is NOT PBS listed in Australia. Ibalizumab (IBA) a monoclonal antibody that is NOT PBS listed in Australia. Discontinuation or interruption of antiretroviral therapy (ART) may result in viral […]
Management of People with HIV and ART Experience
Management of the Treatment-Experienced Patient: This section has information on Management of the Treatment-Experienced Patient. Please click on the below links or follow the table of contents to access the information you are looking for. Virologic Failure Poor CD4 Cell Recovery Optimizing ART in the Setting of Virologic Suppression Discontinuation or Interruption of ARV
Statin Therapy for People with HIV
Recommendations for the Use of Statin Therapy as Primary Prevention of Atherosclerotic Cardiovascular Disease in People with HIV DHHS Last Updated: February 2024Australian Commentary Last Updated: June 2024 AU Comment: Short Summary An updated recommendation regarding statin therapy in PLHIV has been provided within the DHHS guidelines in February 2024, following the publication of the […]
Early (Acute and Recent) HIV Infection
DHHS Last Updated: September 2024Australian Commentary Last Updated: January 2025 AU Comment: Diagnosis of early HIV infection in Australia When acute HIV-1 infection is suspected, and an anti-HIV antibody and/or antibody/antigen combo test is negative or the western blot is indeterminate, other suitable test options include a nucleic acid test for HIV. However, proviral DNA […]